Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced Non-clear Cell Renal Cell Carcinoma”

232 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 232 results

Early research (Phase 1)Study completedNCT00161187
What this trial is testing

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

Who this might be right for
Cancer
University of Medicine and Dentistry of New Jersey 37
Early research (Phase 1)Study completedNCT05585034
What this trial is testing

Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors

Who this might be right for
Head and Neck Squamous Cell CarcinomaMelanoma Excluding Uveal MelanomaNon-small Cell Lung Cancer, Squamous or Non-squamous+6 more
Xencor, Inc. 60
Testing effectiveness (Phase 2)Ended earlyNCT00491075
What this trial is testing

Pemetrexed Plus Gemcitabine in Renal Cell Cancer

Who this might be right for
Renal Cell Carcinoma
M.D. Anderson Cancer Center 16
Early research (Phase 1)Looking for participantsNCT07300241
What this trial is testing

Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

Who this might be right for
Clear Cell Renal Cell CarcinomaRenal Cell CarcinomaRCC+6 more
Neomorph, Inc 30
Testing effectiveness (Phase 2)Study completedNCT01108445
What this trial is testing

Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma

Who this might be right for
Advanced Non-clear Cell Renal Cell Carcinoma
Duke University 131
Not applicableStudy completedNCT00771147
What this trial is testing

A Trial to Evaluate the Characteristics of Patients Treated for Advanced Renal Cell Carcinoma With Nexavar ®

Who this might be right for
Carcinoma, Renal CellCarcinoma, Renal Cell (Advanced)
Bayer 71
Testing effectiveness (Phase 2)Looking for participantsNCT05086692
What this trial is testing

A Beta-only IL-2 ImmunoTherapY Study

Who this might be right for
Advanced Solid TumorUnresectable Solid TumorClear Cell Renal Cell Carcinoma+34 more
Medicenna Therapeutics, Inc. 115
Early research (Phase 1)Study completedNCT03538028
What this trial is testing

A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies

Who this might be right for
Cervical CancerMicrosatellite Instability (MSI)-High Endometrial CancerGastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ])+14 more
Incyte Biosciences International Sàrl 22
Early research (Phase 1)Study completedNCT00056537
What this trial is testing

ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer

Who this might be right for
Non-Small-Cell Lung CarcinomaRenal Cell CarcinomaPancreatic Cancer
Active Biotech AB 44
Early research (Phase 1)Looking for participantsNCT06147037
What this trial is testing

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

Who this might be right for
Advanced Solid TumorMetastatic Colorectal CarcinomaHead and Neck Squamous Cell Carcinoma+4 more
AstraZeneca 70
Testing effectiveness (Phase 2)Active Not RecruitingNCT04140526
What this trial is testing

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

Who this might be right for
Non Small Cell Lung CancerAdvanced Solid TumorMetastatic Melanoma+16 more
OncoC4, Inc. 733
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07159191
What this trial is testing

Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma

Who this might be right for
Advanced Renal Cell Carcinoma (aRCC)
Peking Union Medical College Hospital 30
Testing effectiveness (Phase 2)Study completedNCT02697591
What this trial is testing

INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced MalignanciesMetastatic Cancer
Incyte Biosciences International Sàrl 100
Not applicableStudy completedNCT00477919
What this trial is testing

E-MOSAIC Electronic Tool to Monitor Symptoms

Who this might be right for
Cancer
Swiss Cancer Institute 264
Testing effectiveness (Phase 2)Study completedNCT03548467
What this trial is testing

Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer

Who this might be right for
Locally Advanced or Metastatic Solid Tumours
Nykode Therapeutics ASA 41
Early research (Phase 1)Study completedNCT03752398
What this trial is testing

XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)

Who this might be right for
Melanoma (Excluding Uveal Melanoma)Cervical CarcinomaPancreatic Carcinoma+13 more
Xencor, Inc. 198
Testing effectiveness (Phase 2)Study completedNCT01538238
What this trial is testing

Pazopanib_NCRCC,Ph2 STUDY

Who this might be right for
Locally Advanced or Metastatic Non-clear Cell Type Renal Cell Carcinoma
Samsung Medical Center 10
Testing effectiveness (Phase 2)Ended earlyNCT04260802
What this trial is testing

Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers

Who this might be right for
CancerNeoplasmsMetastatic Cancer+16 more
Ocellaris Pharma, Inc. 73
Testing effectiveness (Phase 2)Study completedNCT01178411
What this trial is testing

An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols

Who this might be right for
Advanced Solid Tumors
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) 60
Not applicableEnded earlyNCT04106167
What this trial is testing

Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy

Who this might be right for
Advanced Solid TumorLymphomaGastric Cancer+15 more
Fate Therapeutics 20
Load More Results